After hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for a deal

Kronos Bio, the drug developer long led by Gilead veteran Norbert Bischofberger, is calling it quits. The biotech said Thursday it's selling to Tang Capital's shell company Concentra Biosciences for 57 ...

Related Posts

Halozyme launches patent fight over Merck's injectable ...

Apr 24, 2025  0

Top pharma companies increased lobbying spend at start ...

Apr 23, 2025  0

Immunic’s stock falls on multiple sclerosis data; Entra...

Apr 30, 2025  0

Comments

Name

Email

Comment

Post Comment